Current / Ongoing Studies                                                                                                                                                                                    Updated August 2021

No Study Name/Phase Type Sponsor Population (Gender/Age) Enrolled / (Target if still enrolling) Period
1 HVTN 702/Phase IIb HIV Vaccine HVTN ♂/♀18-35 yrs 483 2016 – 2021
2 HVTN 705/Phase IIb HIV Vaccine Janssen/HVTN ♀18-35 yrs 144 2018 – 2021
3 NC008/Phase IIc TB Treatment TB Alliance ♂/♀≥18 33 2018 – 2020
4 PrEPARE Study/PrEP Rollout PrEP RTI ♀16-24 yrs  n/a 2019 – 2021
5 EPI RSV RSV study GSK ♀ 18-45 100 2019 – 2020
6 R01 AI147681 KHARITUWE TB MIGRATION STUDY TB Tracing John Hopkins University ♂/♀ 0-99 yrs target 7200 2020 – 2025
7 NN9924-4309 (Pioneer 12) Diabetes (China) Novo Nordisk ♂+♀ ≥18 2 2020 – 2022
8 ChAdOx1 nCoV-19 Covid Vaccine Bill & Melinda Gates and SAMRC ♂+♀

18-65

417 2020 – 2021
9 C3671008 RSV Vaccine Pfizer ♀   ≥18 and ≤49 target 120 2020 – 2023
10 2019nCoV-501_Vaccine_Study Covid Vaccine Novavax ♂+♀ 18-64 324 2020 – 2021
11 VAC31518COV3001 Covid Vaccine Janssen ♂+♀

≥18 and ≤60 & ≥60

306 2020 – 2022
12 Crown Coronation Study Covid PrEP WRHI ♂+♀

≥18 and ≤60 & ≥60

60 2020 – 2021
13 HVTN 405 Covid observational CoVPN ♂/♀ ≥18 target 15 2020 – 2021
14 CoVPN5001 / HVTN5001 Covid observational CoVPN ♂+♀ ≥18 Target 15 2020 – 2021
15 The CARE Project Behavioural Study DSI NRF Surveys Target 100 2021
16 ACTIV-2 A5401 COVID IV Infusion PPD ♂+♀ ≥18 Target 75 2021 – 2022
17 212171 (RSV MAT-009) RSV Vaccine GSK ♀  18 – 49 Target 250 2021 – 2023
18 MK8591-022 IMPOWER Oral PrEP MSD ♀   18 – 45 Target 300 2021 – 2025
19 SRC Geo-Mapping project Behavioural SRC n/a n/a 2021
20 HVTN RAMP Behavioural HVTN MSM &Transgender ♂ ≥18;

Transgender ♀ ≥18

200 May 2021 – May 2022
21 HVTN 702/705 Mapping Behavioural SRC ♂/♀18-35 yrs n/a 2020-2021